9 October 2018
The GHP and the Federation of German Industries e. V. (BDI), jointly organised the workshop “Trade Opportunities for the German Healthcare industry in the Chinese Healthcare Market” in Berlin.
China, the world’s most populous country, has a high demand for healthcare products. Economic prosperity and rising health awareness among the population enable China to invest more in its healthcare industry. With the goals “Made in China 2025” and “Healthy China 2030”, the demand for high-tech, high quality healthcare products rises. Thus, high-tech and high-Quality healthcare products with the designation of origin “Made in Germany” have a unique selling point on the Chinese healthcare market. Hopefully, China will make full use of German medical technology to achieve their goals.
The workshop started with opening remakrs by Mr. Roland Göhde, Chairman of the board of the GHP, and Dr Stefan Mair, member of the executive board of the Federation of German Industries, followed by an interesting kick-off presentations by represenatives of the Ministry of Economy and Energy as well as representatives from the pharmaceuticals and medical devices sectors.
Experts also addressed the challenges within the Chinese healthcare market. First and foremost, their protectionist policies put pressure on German companies with activities on Chinese markets. Moreover companies have difficulties with accessing responsible authorities, constant changes in the regulations, restricted availability of relevant information, double checks on products, delay of approval, high and unclear requirements at clinical tests. Unfortunately, German companies have no rights when they compete with Chinese companies.